A 28-year-old woman with HIV-1 infection (CD4 count 180 cells/μL, viral load 200,000 copies/mL) is pregnant at 18 weeks gestation. She has never received antiretroviral therapy. Which of the following is the preferred first-line regimen to prevent mother-to-child transmission (PMTCT) and treat her advanced immunosuppression?

## Preferred ART Regimen in Pregnant HIV-Positive Women **Key Point:** Dolutegravir-based regimens are now the preferred first-line choice for pregnant women with HIV, including those with advanced immunosuppression, due to superior efficacy, safety, and PMTCT outcomes. ### Why DTG is Preferred in Pregnancy **High-Yield:** Dolutegravir advantages in pregnancy: - **No teratogenicity:** Extensive safety data in pregnancy (no increased birth defects) - **Superior PMTCT efficacy:** Rapid viral suppression reduces transmission risk - **Once-daily dosing:** Improves adherence - **Minimal drug interactions:** Safe with other medications - **Excellent placental transfer:** Achieves adequate fetal concentrations - **Recommended by WHO, DHHS, and NACO** for pregnant women ### Comparison of Regimens in Pregnancy | Regimen | Teratogenicity Risk | PMTCT Efficacy | Adherence | Current Status | |---------|-------------------|----------------|-----------|----------------| | **DTG + TDF + 3TC** | None | Excellent (>98%) | Excellent (OD) | **Preferred** | | Efavirenz + 2 NRTIs | Possible (CNS defects) | Good | Fair (TID dosing) | Avoid (historical) | | PI/r + 2 NRTIs | None | Good | Poor (BD, GI side effects) | Second-line | | Raltegravir + 2 NRTIs | None | Good | Fair (BD dosing) | Alternative | **Clinical Pearl:** Efavirenz was historically used in pregnancy but is now **contraindicated** due to potential neural tube defects in the first trimester. This patient is at 18 weeks — DTG is the safest choice. ### PMTCT Strategy with DTG **Mnemonic:** **DTG-TDF-3TC in Pregnancy = "Dolutegravir Transmits To Genes safely"** — safe for mother and fetus. 1. **Maternal viral suppression:** DTG achieves undetectable viral load within 4–8 weeks 2. **Placental transfer:** DTG crosses placenta effectively, protecting the fetus 3. **Infant prophylaxis:** Maternal DTG levels in breast milk provide post-natal protection (if breastfeeding) 4. **Delivery planning:** Undetectable = untransmittable (U=U); vaginal delivery safe if viral load <50 copies/mL ### Guideline Recommendation **High-Yield:** WHO 2023, DHHS Perinatal Guidelines, and NACO all recommend **DTG-based regimens as first-line for pregnant women**, including those with CD4 <200 cells/μL. [cite:Harrison 21e Ch 197]